NEW YORK (TheStreet) -- Shares of Eli Lilly  (LLY) were sliding in early-afternoon trading on Tuesday after Senator Bernie Sanders (I-VT) criticized the price increase of the company's Humalog insulin.

Why has the price of Humalog insulin gone up 700% in 20 years? It's simple. The drug industry's greed. pic.twitter.com/SUeSbsr2Ka

— Bernie Sanders (@SenSanders) November 1, 2016

The price of Humalog has surged to more than $250 per vial from $21 a vial over the past 20 years, according to the Washington Post. The treatment generated $640.8 million in third-quarter revenue for Eli Lilly.

Drug makers such as Eli Lilly have come under fire recently for drastically hiking the price of certain treatments. 

Separately, TheStreet Ratings team rates the stock as a "buy" with a ratings score of B+.

Eli Lilly's strengths such as its revenue growth and expanding profit margins outweigh the fact that the company has had lackluster performance in the stock itself.

You can view the full analysis from the report here: LLY

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author. 

If you liked this article you might like

Jim Cramer: Drug Stocks on the Move

Jim Cramer: Drug Stocks on the Move

Here's How Eli Lilly Stock Can Regain Its Footing

Here's How Eli Lilly Stock Can Regain Its Footing

Intermediate Trade: Eli Lilly

Intermediate Trade: Eli Lilly

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls